Literature DB >> 12752402

Clinical characteristics of the alpha-synuclein mutation (G209A)-associated Parkinson's disease in comparison with other forms of familial Parkinson's disease in Greece.

S Papapetropoulos1, J Ellul, C Paschalis, A Athanassiadou, A Papadimitriou, T Papapetropoulos.   

Abstract

An Ala53Thr mutation of the alpha-synuclein has been recently identified as a rare cause of familial Parkinson's disease (fPD). In the present study, the clinical characteristics of Parkinson's disease (PD) patients with Ala53Thr alpha-synuclein mutation (alpha-synPD) were compared with fPD patients without any known mutation. An investigator blinded to the results of the genetic analysis examined 15 alpha-synPD patients and 43 consecutive fPD patients. Demographic data, age at onset of the illness, duration of the disease and modality of presentation were collected. Segregation ratios for both sexes in individuals at risk of developing alpha-synPD were estimated. The Unified Parkinson's disease rating scale (UPDRS) was also completed. The 15 alpha-synPD patients were matched for duration of the disease and age at onset with 15 of the 43 fPD patients (MfPD). Comparisons were also made between 14 patients belonging to three multicase families with patterns of inheritance similar to alpha-synPD. The alpha-synPD patients were significantly younger (mean difference 11.8 years) and showed the first sign of the disease earlier in life (mean difference 12.7 years) as compared with the fPD patients. Tremor at onset was present in only one (6.7%) of the alpha -synPD patients compared with 18 (41.9%) of the fPD patients (P = 0.01). At the time of examination rigidity, postural instability, orthostatic hypotension and the overall clinical severity did not differ significantly either between alpha-synPD and fPD or between alpha-synPD and MfPD groups. Nevertheless, some clinically relevant trends concerning the psychiatric symptoms and complications of therapy were recognized. The overall clinical severity and the progression of the disease in patients with alpha-synPD did not differ from that of the fPD patients. The alpha-synPD patients presented the illness at a younger age and also had lower prevalence of tremor when compared with the fPD patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12752402     DOI: 10.1046/j.1468-1331.2003.00576.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  8 in total

1.  A Swedish family with de novo alpha-synuclein A53T mutation: evidence for early cortical dysfunction.

Authors:  Andreas Puschmann; Owen A Ross; Carles Vilariño-Güell; Sarah J Lincoln; Jennifer M Kachergus; Stephanie A Cobb; Suzanne G Lindquist; Jørgen E Nielsen; Zbigniew K Wszolek; Matthew Farrer; Håkan Widner; Danielle van Westen; Douglas Hägerström; Katerina Markopoulou; Bruce A Chase; Karin Nilsson; Jan Reimer; Christer Nilsson
Journal:  Parkinsonism Relat Disord       Date:  2009-07-25       Impact factor: 4.891

Review 2.  α-Synuclein and Parkinsonism: Updates and Future Perspectives.

Authors:  Kaie Rosborough; Neha Patel; Lorraine V Kalia
Journal:  Curr Neurol Neurosci Rep       Date:  2017-04       Impact factor: 5.081

3.  Baicalein reduces E46K alpha-synuclein aggregation in vitro and protects cells against E46K alpha-synuclein toxicity in cell models of familiar Parkinsonism.

Authors:  Mali Jiang; Yair Porat-Shliom; Zhong Pei; Yong Cheng; Lan Xiang; Katherine Sommers; Qing Li; Frank Gillardon; Bastian Hengerer; Cynthia Berlinicke; Wanli W Smith; Donald J Zack; Michelle A Poirier; Christopher A Ross; Wenzhen Duan
Journal:  J Neurochem       Date:  2010-04-19       Impact factor: 5.372

4.  A population-based study of parkinsonism in an Amish community.

Authors:  Brad A Racette; Laura M Good; Abigail M Kissel; Susan R Criswell; Joel S Perlmutter
Journal:  Neuroepidemiology       Date:  2009-07-27       Impact factor: 3.282

5.  Gain-of-function variant in GLUD2 glutamate dehydrogenase modifies Parkinson's disease onset.

Authors:  Andreas Plaitakis; Helen Latsoudis; Konstantinos Kanavouras; Beate Ritz; Jeff M Bronstein; Irene Skoula; Vasileios Mastorodemos; Spyridon Papapetropoulos; Nikolas Borompokas; Ioannis Zaganas; Georgia Xiromerisiou; George M Hadjigeorgiou; Cleanthe Spanaki
Journal:  Eur J Hum Genet       Date:  2009-10-14       Impact factor: 4.246

Review 6.  Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update.

Authors:  Karen Nuytemans; Jessie Theuns; Marc Cruts; Christine Van Broeckhoven
Journal:  Hum Mutat       Date:  2010-07       Impact factor: 4.878

7.  Mitochondrial therapy for Parkinson's disease: neuroprotective pharmaconutrition may be disease-modifying.

Authors:  Richard Kones
Journal:  Clin Pharmacol       Date:  2010-09-17

Review 8.  Multiple system atrophy: genetic or epigenetic?

Authors:  Edith Sturm; Nadia Stefanova
Journal:  Exp Neurobiol       Date:  2014-12-12       Impact factor: 3.261

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.